Valeant Pharmaceuticals International announces marketing information for Siliq (brodalumab), a new treatment for psoriasis.

Valeant Pharmaceuticals International, Inc. announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the company has decided to list Siliq (brodalumab) injection, at $3,500 per month, which is the lowest injectable biologic psoriasis treatment currently on the market. Siliq will also be included in the company's patient access program to further offer financial support and access to patients.

Siliq, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Siliq is the only product that included the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint. The sales and marketing of Siliq are expected to commence in the U.S. during the second half of 2017.